Key points are not available for this paper at this time.
CAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies such as acute lymphoblastic leukemia, follicular lymphoma, and mantle cell lymphoma. Recently approved T lymphocyte-based therapies demonstrated the potential for improved outcomes in solid tumor malignancies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jennifer N. Brudno
Marcela V. Maus
Christian S. Hinrichs
JAMA
National Institutes of Health
Massachusetts General Hospital
National Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Brudno et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69de37b01c2d3320f8b0be91 — DOI: https://doi.org/10.1001/jama.2024.19462
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: